Global Blood Therapeutics, Inc. (GBT)
(Delayed Data from NSDQ)
$55.18 USD
+1.34 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[GBT]
Reports for Purchase
Showing records 1 - 20 ( 340 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Pfizer to Acquire GBT for $5.4B; D/G to Neutral; Q2 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Ph2 Portion of Ph2/3 for ''601/SCD Initiated; Initial Ph2 Data By YE:22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Real-World Oxbryta and ''601 Ph1 Data Highlighted at EHA 2022; R&D Update
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Industry: Medical - Biomedical and Genetics
Real-World Evidence Reinforces, Underscores Oxbryta Benefit
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Considerations Ahead of GBT601 Presentation at EHA 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
All Eyes on GBT601 in 2022; Reit. Buy and Lowering PT to $65 from $75
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A